CN108350077A - 产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法 - Google Patents

产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法 Download PDF

Info

Publication number
CN108350077A
CN108350077A CN201680063800.5A CN201680063800A CN108350077A CN 108350077 A CN108350077 A CN 108350077A CN 201680063800 A CN201680063800 A CN 201680063800A CN 108350077 A CN108350077 A CN 108350077A
Authority
CN
China
Prior art keywords
hscs
cells
antibodies
population
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680063800.5A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·L·麦格纳尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crescent Biopharma Inc
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Publication of CN108350077A publication Critical patent/CN108350077A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
CN201680063800.5A 2015-11-03 2016-11-02 产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法 Pending CN108350077A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250424P 2015-11-03 2015-11-03
US62/250,424 2015-11-03
PCT/US2016/060014 WO2017079215A1 (en) 2015-11-03 2016-11-02 Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same

Publications (1)

Publication Number Publication Date
CN108350077A true CN108350077A (zh) 2018-07-31

Family

ID=57539587

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680063800.5A Pending CN108350077A (zh) 2015-11-03 2016-11-02 产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法

Country Status (6)

Country Link
US (1) US20180320136A1 (https=)
EP (1) EP3371222A1 (https=)
JP (1) JP2019503985A (https=)
CN (1) CN108350077A (https=)
CA (1) CA3002880A1 (https=)
WO (1) WO2017079215A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053892A (zh) * 2018-09-19 2018-12-21 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110755608A (zh) * 2018-07-27 2020-02-07 上海微创医疗器械（集团）有限公司 一种特异性抗体的用途、一种植入医疗器械及其制备方法
WO2020158943A1 (ja) * 2019-02-01 2020-08-06 住友化学株式会社 抗体及びその機能性断片
US20240075063A1 (en) * 2020-12-10 2024-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mait cells for controlling graft versus host disease

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280611A (zh) * 1997-09-25 2001-01-17 糖技术公司 结合造血干细胞的方法和组合物
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
CN101848991A (zh) * 2007-08-08 2010-09-29 协和发酵麒麟株式会社 分离的细胞群
US20100292095A1 (en) * 2007-11-09 2010-11-18 Suomen Punainen Risti, Veripalvelu Human monoclonal antibodies directed to sialyl lewis c, sialyl tn and n glycolylneuraminic acid epitopes and a method of analysis of stem cells comprising said epitopes
CN101896200A (zh) * 2007-12-06 2010-11-24 Csl有限公司 抑制白血病干细胞的方法
WO2012045913A1 (en) * 2010-10-06 2012-04-12 Suomen Punainen Risti, Veripalvelu Method for isolating cells and a cell population thereof
US20120093782A1 (en) * 2009-05-13 2012-04-19 Grove Robert I Enhanced Hematopoietic Stem Cell Engraftment

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
FR2596413B1 (fr) 1986-03-27 1988-06-10 Merieux Inst Nouveaux milieux de culture de bacteries appartenant au genre bordetella, contenant des derives etherifies de polymeres de d-glucose, et leur application
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US5965457A (en) * 1995-06-06 1999-10-12 Magnani; John L. Methods of screening for a candidate compound able to bind to CD34+ cells
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
US6043348A (en) * 1996-11-13 2000-03-28 Lawman; Michael J. P. Antibody recognizing a small subset of human hematopoietic cells
AU4336599A (en) 1998-06-08 1999-12-30 Osiris Therapeutics, Inc. (in vitro) maintenance of hematopoietic stem cells
DK1141028T3 (da) 1998-12-23 2010-05-25 Pfizer Humane monoklonale antistoffer til CTLA-4
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
EP2115460A4 (en) * 2007-01-18 2010-01-13 Suomen Punainen Risti Veripalv NEW CARBOHYDRATE FROM HUMAN CELLS AND METHOD FOR THE ANALYSIS AND MODIFICATION THEREOF
FI20095459A0 (fi) * 2009-04-24 2009-04-24 Suomen Punainen Risti Veripalv Uusia määritysmenetelmiä
WO2012039430A1 (ja) * 2010-09-21 2012-03-29 株式会社Ｇｐバイオサイエンス がん幹細胞の単離方法
US8464599B2 (en) 2011-01-10 2013-06-18 GM Global Technology Operations LLC Eight speed dual clutch transmission

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280611A (zh) * 1997-09-25 2001-01-17 糖技术公司 结合造血干细胞的方法和组合物
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
CN101848991A (zh) * 2007-08-08 2010-09-29 协和发酵麒麟株式会社 分离的细胞群
US20100303766A1 (en) * 2007-08-08 2010-12-02 Kyowa Hakko Kirin Co., Ltd. Cell population with enhanced transplantation activity
US20100292095A1 (en) * 2007-11-09 2010-11-18 Suomen Punainen Risti, Veripalvelu Human monoclonal antibodies directed to sialyl lewis c, sialyl tn and n glycolylneuraminic acid epitopes and a method of analysis of stem cells comprising said epitopes
CN101896200A (zh) * 2007-12-06 2010-11-24 Csl有限公司 抑制白血病干细胞的方法
US20120093782A1 (en) * 2009-05-13 2012-04-19 Grove Robert I Enhanced Hematopoietic Stem Cell Engraftment
WO2012045913A1 (en) * 2010-10-06 2012-04-12 Suomen Punainen Risti, Veripalvelu Method for isolating cells and a cell population thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEMMORANTA H等: "N-glycan structures and associated gene expression reflect the characteristic N-glycosylation pattern of human hematopoietic stem and progenitor cell", 《EXP HEMATOL》 *
廖子君: "《肿瘤转移学》", 《肿瘤转移学》 *
林果为 著: "《现代临床血液病学》", 《现代临床血液病学》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053892A (zh) * 2018-09-19 2018-12-21 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
CN109053892B (zh) * 2018-09-19 2021-03-26 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
US11976129B2 (en) 2018-09-19 2024-05-07 Acroimmune Biotech Co., Ltd. Monoclonal antibody specifically binding human and monkey CD38 antigens, preparation method and use thereof

Also Published As

Publication number Publication date
JP2019503985A (ja) 2019-02-14
WO2017079215A1 (en) 2017-05-11
US20180320136A1 (en) 2018-11-08
EP3371222A1 (en) 2018-09-12
CA3002880A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
JP7451627B2 (ja) キメラ受容体及びその使用方法
JP2022106807A (ja) Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法
US20240207428A1 (en) Compositions and methods for the depletion of cells
BR112017014361B1 (pt) Uso de uma população de células-tronco mesenquimais (MSCS) modificadas com fucosiltransferase VI (FTVI) que expressa o ligante de E-L Selectina de célula hematopoiética (HCELL) para tratar diabetes
CN108350077A (zh) 产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法
JP2024023226A (ja) 造血幹細胞及び前駆細胞を動員させるための投薬レジメン
CA3078963A1 (en) Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
JP2006528627A (ja) アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物
CN103360494B (zh) 抗cd20的全人源单克隆抗体及其应用
WO2023208157A1 (zh) 靶向cd19的嵌合抗原受体及其应用
US10961308B2 (en) Embigin inhibition for promotion of hematopoietic stem and progenitor cell expansion
CA3137568A1 (en) Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
AU692465B2 (en) Monoclonal antibody that recognizes interstitial cell surface antigen
KR102919638B1 (ko) 자연살해세포 및 car-nk 세포의 제조 방법, 이에 따라 제조된 자연살해세포 및 car-nk 세포, 및 이의 용도
WO2025061028A1 (zh) 一种修饰细胞的方法及其应用
CN120359242A (zh) 靶向cd117和cd3的双特异性抗体
Rummage et al. Conventional versus low dose rituximab in the treatment of steroid-refractory chronic graft versus host disease
HK40091146A (zh) 改善细胞治疗的方法
JP2022543779A (ja) イムノコンジュゲート
HK40063038B (zh) 靶向dll3的嵌合抗原受体和结合剂
Rocha et al. 22: Outcomes after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia: A Eurocord-Netcord Survey
BR112018070187B1 (pt) Receptores quiméricos para a flt3, polinucleotídeo, polipeptídeo e vetor relacionados e uso dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731